BridgeBio Pharma, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-22$79.91 RISE2026-02-05$63.73 PEAK2026-04-14$77.93 82d | -20.2% 14d | Missed | Missed | — | — | +22.3% 68d | Missed |
DROP2025-05-02$38.57 RISE2025-05-28$32.26 PEAK2025-08-15$51.32 105d | -16.4% 26d | Missed | Missed | — | — | +59.1% 79d | Missed |
DROP2025-01-24$37.59 RISE2025-04-08$30.14 PEAK2025-06-26$45.12 153d | -19.8% 74d | Missed | Missed | — | — | +49.7% 79d | Missed |
DROP2024-09-05$31.30 RISE2024-11-18$22.35 PEAK2025-01-24$37.59 141d | -28.6% 74d | Missed | Missed | — | — | +68.2% 67d | Missed |
DROP2024-09-05$31.30 RISE2024-10-09$23.38 PEAK2024-12-09$29.50 95d | -25.3% 34d | Missed | Missed | — | — | +26.2% 61d | Missed |
DROP2024-05-16$31.04 RISE2024-08-13$23.91 PEAK2024-09-05$31.30 112d | -23.0% 89d | Missed | Missed | — | — | +30.9% 23d | Missed |
DROP2024-02-15$39.23 RISE2024-06-24$23.00 PEAK2024-09-05$31.30 203d | -41.4% 130d | Missed | Missed | — | — | +36.1% 73d | Missed |
DROP2023-12-27$43.89 RISE2024-04-25$24.33 PEAK2024-05-16$31.04 141d | -44.6% 120d | Missed | Missed | — | — | +27.6% 21d | Missed |
DROP2023-07-31$35.01 RISE2023-10-04$24.02 PEAK2023-12-27$43.89 149d | -31.4% 65d | Missed | Missed | — | — | +82.7% 84d | Missed |
DROP2023-03-07$18.55 RISE2023-05-24$13.29 PEAK2023-07-31$35.01 146d | -28.4% 78d | Missed | Missed | — | — | +163.4% 68d | Missed |
DROP2022-09-12$12.36 RISE2022-12-28$6.74 PEAK2023-03-07$18.55 176d | -45.5% 107d | Missed | Missed | — | — | +175.2% 69d | Missed |
DROP2022-09-12$12.36 RISE2022-09-26$9.13 PEAK2022-10-04$11.52 22d | -26.1% 14d | Missed | Missed | — | — | +26.2% 8d | Missed |
DROP2022-04-06$12.14 RISE2022-08-03$7.94 PEAK2022-09-12$12.36 159d | -34.6% 119d | Missed | Missed | — | — | +55.7% 40d | Missed |
DROP2022-04-06$12.14 RISE2022-06-13$5.95 PEAK2022-08-10$11.99 126d | -51.0% 68d | Missed | Missed | — | — | +101.5% 58d | Missed |
DROP2022-01-03$17.16 RISE2022-05-11$5.21 PEAK2022-08-08$11.93 217d | -69.6% 128d | Missed | Missed | — | — | +129.0% 89d | Missed |
1–15 / 22 1 / 2 | |||||||
David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $94 to $98.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $110 price target.
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026, and BridgeBio is poised to launch BBP-418 upon approval. The FDA also notified the Company that it is not currently
Intel downgraded, Marvell upgraded: Wall Street's top analyst calls
Raymond James analyst Martin Auster downgrades BridgeBio Pharma (NASDAQ:BBIO) from Outperform to Market Perform.
BridgeBio Pharma (NASDAQ:BBIO) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company’s transthyretin amyloid cardiomyopathy (ATTR-CM) franchise. The call contrasts with Citi’s simultaneous Buy initiation Buy ratings on peer biotechs Alnylam, Ascendis Pharma, BioMarin, Cytokinetics, and of Ionis Pharmaceuticals (NASDAQ:IONS), making the BBIO Neutral a cautious outlier. For ... Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls
Citigroup analyst Eric Joseph initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Neutral rating and announces Price Target of $82.
FDA leadership shake-up update and what it means for Pfizer: valuation, dividend yield, and Padcev growth.
BridgeBio Pharma recently filed a New Drug Application with the FDA for encaleret in autosomal dominant hypocalcemia type 1, following Phase 3 CALIBRATE results showing rapid, durable improvements in calcium control and a favorable safety profile. Alongside this, new ATTRibute-CM data and fresh global approvals for acoramidis (Attruby/BEYONTTRA) highlight BridgeBio’s progress in turning its rare disease pipeline into commercial products across multiple geographies. We’ll now examine how...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 8 Most Promising Biotech Stocks to Buy Now. On May 8, Evercore ISI raised its price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $130 from $125. It maintained an “Outperform” rating on the stock. On May 7, BridgeBio Pharma, Inc. (NASDAQ:BBIO) posted first-quarter 2026 results, showing $194.5 […]
BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three potential near-term product launches from the company’s late-stage pipeline. Tom Trimarchi, BridgeBi
BridgeBio Pharma, Inc. (BBIO) Bank of America Global Healthcare Conference 2026 May 12, 2026 5:20 PM EDTCompany ParticipantsThomas Trimarchi - CFO &...
2026-05-13. The following slide deck was published by BridgeBio Pharma, Inc.
Presenter SpeechJason Zemansky The afternoon session on this our first day at the Annual Healthcare Conference in Tosti Las Vegas. My name is Jason Zemansky. I'm 1 of the mid-cap analysts here at...
An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ATTR-CM.
BridgeBio Pharma Inc: BridgeBio submits NDA to FDA for encaleret for individuals living with ADH1 BridgeBio Pharma Inc - encaleret may be eligible for Priority Review; United States launch...
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1- All pre-specified primary and
Encaleret Restores Mineral Homeostasis in Autosomal Dominant Hypocalcemia Type 1 : Primary Results from the Phase 3 CALIBRATE Trial Presenting author: Prof. Filomena Cetani, Italy ...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BBIO | -3.35% | +1.16% | -13.37% | +93.46% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -6.32% | +6.88% | -9.93% | +80.77% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Viking | long/short | 11.84M | $879.42M | 2.46% | Trimmed-17.7% | 2026-03-31 |
| StateStreet | passive | 4.93M | $366.42M | 0.01% | Trimmed-0.6% | 2026-03-31 |
| TwoSigma | quant | 3.12M | $231.74M | 0.19% | Added+60.3% | 2026-03-31 |
| DEShaw | quant | 2.55M | $189.03M | 0.11% | Added+15.0% | 2026-03-31 |
| Wellington | fundamental | 2.48M | $184.46M | 0.03% | Added+5.8% | 2026-03-31 |
| FidelityFMR | fundamental | 2.34M | $174.05M | 0.01% | Trimmed-1.9% | 2026-03-31 |
| CapResearch | fundamental | 763.7K | $56.71M | 0.01% | Trimmed-60.5% | 2026-03-31 |
| RenTech | quant | 365.8K | $27.16M | 0.04% | New | 2026-03-31 |
| Bridgewater | macro | 259.5K | $19.27M | 0.09% | Added+501.0% | 2026-03-31 |
| TRowePrice | fundamental | 3.80M | $282.31K | 0.03% | Trimmed-0.7% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-04upcoming | -0.58 | — | — |
| 2026-05-07 | -0.62 | -0.84 | -36.22% |
| 2026-02-24 | -0.62 | -0.94 | -50.63% |
| 2025-10-29 | -0.78 | -0.72 | +7.73% |
| 2025-08-05 | -0.60 | -0.95 | -57.12% |
| 2025-04-29 | -1.00 | -0.99 | +0.87% |
| 2025-02-20 | -1.09 | -1.37 | -26.09% |
| 2024-11-12 | -0.86 | -1.08 | -25.14% |
| 2024-08-01 | -0.94 | -1.01 | -7.24% |
| 2024-05-02 | -0.54 | -0.12 | +77.01% |
| 2024-02-22 | -0.80 | -0.96 | -20.13% |
| 2023-11-02 | -0.89 | -1.08 | -21.57% |
| 2023-08-03 | -0.87 | -0.96 | -9.94% |
| 2023-05-04 | -0.83 | -0.90 | -7.70% |
| 2023-02-23 | -0.94 | -0.87 | +7.30% |
| 2022-11-03 | -1.01 | -0.89 | +11.25% |